TBE
MCID: TCK001
MIFTS: 56

Tick-Borne Encephalitis (TBE)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Tick-Borne Encephalitis

MalaCards integrated aliases for Tick-Borne Encephalitis:

Name: Tick-Borne Encephalitis 12 76 53 59 15 73
Siberian Tick-Borne Encephalitis 12 73
Western European Tick-Borne Encephalitis 12
Russian Spring-Summer Encephalitis 12
Encephalitis, Far Eastern Russian 73
Encephalitis, Central European 73
Central European Encephalitis 12
West-Siberian Encephalitis 12
Encephalitis, Tick-Borne 44
Encephalitis Tick-Borne 55
Taiga Encephalitis 12
Far Eastern Tbe 12
Tbe 59

Characteristics:

Orphanet epidemiological data:

59
tick-borne encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050175
ICD10 33 A84.1
ICD9CM 35 063.2
MeSH 44 D004675
SNOMED-CT 68 16901001
Orphanet 59 ORPHA297
MESH via Orphanet 45 D004675
UMLS via Orphanet 74 C0014061
ICD10 via Orphanet 34 A84.0 A84.1 A84.8 more

Summaries for Tick-Borne Encephalitis

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain, has material basis in Tick-borne encephalitis virus, which is transmitted by Ixodes ticks. The infection has symptom drowsiness, has symptom confusion, has symptom sensory disturbances, and has symptom paralysis.

MalaCards based summary : Tick-Borne Encephalitis, also known as siberian tick-borne encephalitis, is related to encephalitis and west nile virus, and has symptoms including paralysis, confusion and drowsiness. An important gene associated with Tick-Borne Encephalitis is SCRIB (Scribbled Planar Cell Polarity Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Formaldehyde and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells, and related phenotype is neoplasm.

Wikipedia : 76 Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The... more...

Related Diseases for Tick-Borne Encephalitis

Diseases related to Tick-Borne Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.9 CCR5 CD209 CXCL10 SCRIB TLR3
2 west nile virus 30.7 CCR5 CD209 OAS1 TLR3
3 hemorrhagic fever 30.6 ALB CD209 IL10
4 herpes simplex encephalitis 30.5 CXCL11 TLR3
5 viral infectious disease 30.5 CCR5 CD209 CXCL10 IL10 OAS1 TLR3
6 japanese encephalitis 30.4 CD209 CXCL10 TLR3
7 mouth disease 30.2 IL10 OAS1 TLR3
8 viral encephalitis 30.0 CXCL10 IL10
9 multiple sclerosis 29.9 CCR5 CXCL10 CXCL11 IL10
10 powassan encephalitis 11.4
11 lyme disease 10.7
12 thrombocytopenia 10.4
13 human granulocytic anaplasmosis 10.4
14 ehrlichiosis 10.4
15 dengue virus 10.4
16 meningoencephalitis 10.4
17 tick infestation 10.4
18 meningitis 10.4
19 louping ill 10.3
20 kyasanur forest disease 10.3
21 vaccinia 10.3
22 herpes simplex 10.3
23 venezuelan equine encephalitis 10.3
24 poliomyelitis 10.2
25 adamantinoma of long bones 10.2
26 tetanus 10.2
27 crimean-congo hemorrhagic fever 10.2
28 influenza 10.2
29 neuropathy 10.2
30 orofacial granulomatosis 10.2 CCR5 IL10
31 west nile encephalitis 10.1 OAS1 OAS3
32 mucocutaneous leishmaniasis 10.1 CCR5 IL10 TLR3
33 chronic graft versus host disease 10.1 ALB IL10
34 fascioliasis 10.1 ALB IL10
35 myositis 10.1
36 rheumatoid arthritis 10.1
37 schizophrenia 10.1
38 disorganization, mouse, homolog of 10.1
39 noonan syndrome 5 10.1
40 alopecia 10.1
41 arthritis 10.1
42 dengue disease 10.1
43 hepatitis 10.1
44 hepatitis b 10.1
45 zika fever 10.1
46 mumps 10.1
47 st. louis encephalitis 10.1
48 optic neuritis 10.1
49 rift valley fever 10.1
50 coccidioidomycosis 10.1

Graphical network of the top 20 diseases related to Tick-Borne Encephalitis:



Diseases related to Tick-Borne Encephalitis

Symptoms & Phenotypes for Tick-Borne Encephalitis

Symptoms:

12
  • paralysis
  • confusion
  • drowsiness
  • sensory disturbances

MGI Mouse Phenotypes related to Tick-Borne Encephalitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALB CCR5 IL10 SCRIB TLR3

Drugs & Therapeutics for Tick-Borne Encephalitis

Drugs for Tick-Borne Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
5 Immunoglobulins Phase 4,Not Applicable
6 Antibodies Phase 4,Not Applicable
7 Pharmaceutical Solutions Phase 4
8 Anti-Infective Agents Phase 4,Not Applicable
9 Disinfectants Phase 4
10 Polygeline Phase 4
11 Blood Substitutes Phase 4
12 Plasma Substitutes Phase 4
13
Lactitol Investigational Phase 3 585-86-4 3871
14
Doxycycline Approved, Investigational, Vet_approved Not Applicable 564-25-0 54671203
15
Granisetron Approved, Investigational Not Applicable 109889-09-0 3510
16
Acyclovir Approved 59277-89-3 2022
17
Ceftriaxone Approved 73384-59-5 5479530 5361919
18
Dopamine Approved 51-61-6, 62-31-7 681
19 Antipyretics Not Applicable
20 Anti-Bacterial Agents Not Applicable
21 Antiparasitic Agents Not Applicable
22 Antiemetics Not Applicable
23 Antibiotics, Antitubercular Not Applicable
24 Antimalarials Not Applicable
25 Antiprotozoal Agents Not Applicable
26 dipyrone Not Applicable
27 Neurotransmitter Agents
28 Antiviral Agents
29 Dopamine Antagonists
30 Dopamine Agents
31 Peripheral Nervous System Agents
32 Gastrointestinal Agents
33 Autonomic Agents

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
2 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
3 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4 TicoVac
4 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
5 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Completed NCT00894686 Phase 4
6 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
7 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
8 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
9 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
10 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
11 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
12 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
13 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
14 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
15 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® Completed NCT02511587 Phase 4
16 TBE Vaccination in Allergic Patients Completed NCT02511535 Phase 4
17 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Active, not recruiting NCT03294135 Phase 4
18 Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Completed NCT01361776 Phase 2, Phase 3
19 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children Completed NCT00840801 Phase 3
20 FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years Completed NCT00161876 Phase 3
21 Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years Completed NCT00161746 Phase 2, Phase 3
22 Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR Completed NCT00161824 Phase 3
23 Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
24 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines Completed NCT00644059 Phase 3
25 New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Active, not recruiting NCT02318069 Phase 2, Phase 3
26 Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine Unknown status NCT00890422 Phase 2
27 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients Completed NCT01991067 Phase 2
28 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
29 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
30 FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years Completed NCT00161889 Phase 2
31 FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years Completed NCT00161850 Phase 2
32 Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) Terminated NCT01031537 Phase 2
33 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Completed NCT00118924 Phase 1
34 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
35 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis Completed NCT02275741
36 Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children Completed NCT00163618
37 Tick-borne Encephalitis and Positive Borrelial Antibodies Recruiting NCT02463942 Not Applicable Doxycycline;Symptomatic therapy
38 Aseptic Meningoencephalitis in Slovenia Recruiting NCT02328469 symptomatic therapy;Ceftriaxone or Doxycycline;Acyclovir

Search NIH Clinical Center for Tick-Borne Encephalitis

Cochrane evidence based reviews: encephalitis, tick-borne

Genetic Tests for Tick-Borne Encephalitis

Anatomical Context for Tick-Borne Encephalitis

MalaCards organs/tissues related to Tick-Borne Encephalitis:

41
Brain, Testes, T Cells, B Cells, Skin, Spleen, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Tick-Borne Encephalitis:

19
Brain

Publications for Tick-Borne Encephalitis

Articles related to Tick-Borne Encephalitis:

(show top 50) (show all 1024)
# Title Authors Year
1
Emergence of tick-borne encephalitis (TBE) in the Netherlands. ( 30385073 )
2019
2
Self-reported vaccination coverage against tick-borne encephalitis in Slovenia. ( 30197266 )
2019
3
Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia. ( 30197268 )
2019
4
Tick-borne encephalitis (TBE) in children in Europe: Epidemiology, clinical outcome and comparison of vaccination recommendations. ( 30241699 )
2019
5
Continued expansion of tick-borne pathogens: Tick-borne encephalitis virus complex and Anaplasma phagocytophilum in Denmark. ( 30245088 )
2019
6
Report of the 20th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE): ISW-TBE: 20 years of commitment and still challenges ahead. ( 30172555 )
2019
7
The intrathecal expression and pathogenetic role of Th17 cytokines and CXCR2-binding chemokines in tick-borne encephalitis. ( 29678185 )
2018
8
Tick-Borne Encephalitis Virus Nonstructural Protein NS5 Induces RANTES Expression Dependent on the RNA-Dependent RNA Polymerase Activity. ( 29760190 )
2018
9
Development of a serodiagnostic IgM-ELISA for tick-borne encephalitis virus using subviral particles with strep-tag. ( 29960872 )
2018
10
First detection of tick-borne encephalitis virus RNA in clinical specimens of acutely ill patients in Hungary. ( 29373305 )
2018
11
Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017. ( 29386094 )
2018
12
Complete Genomic Characterization of Three Tick-Borne Encephalitis Viruses Detected Along the China-North Korea Border, 2011. ( 29742014 )
2018
13
Tick-borne encephalitis virus, Borrelia burgdorferi sensu lato, Borrelia miyamotoi, Anaplasma phagocytophilum and Candidatus Neoehrlichia mikurensis in Ixodes ricinus ticks collected from recreational islands in southern Norway. ( 29678403 )
2018
14
Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation. ( 29321318 )
2018
15
Probing chemical space of tick-borne encephalitis virus reproduction inhibitors with organoselenium compounds. ( 29709065 )
2018
16
Mechanisms of Antiviral Activity of the Polyphenol Complex from Seagrass of the Zosteraceae Family against Tick-Borne Encephalitis Virus. ( 29797124 )
2018
17
Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody. ( 29382836 )
2018
18
Tick-Borne Encephalitis Virus: A Structural View. ( 29958443 )
2018
19
Erratum for Panayiotou et al., &amp;quot;Viperin Restricts Zika Virus and Tick-Borne Encephalitis Virus Replication by Targeting NS3 for Proteasomal Degradation&amp;quot;. ( 29844247 )
2018
20
Serologic Evidence of Tick-Borne Encephalitis Virus Infection in a Patient with Suspected Lyme Disease in Japan. ( 29848409 )
2018
21
Borrelia burgdorferi sl and tick-borne encephalitis virus coinfection in Eastern France. ( 29449048 )
2018
22
Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature. ( 29313244 )
2018
23
The long-term outcome of tick-borne encephalitis in Central Europe. ( 29275872 )
2018
24
Exposure to West Nile virus and tick-borne encephalitis virus in dogs in Spain. ( 29322674 )
2018
25
Diagnosing tick-borne encephalitis: a re-evaluation of notified cases. ( 29188467 )
2018
26
Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias. ( 29673942 )
2018
27
Comparative genome analysis of Alkhumra hemorrhagic fever virus with Kyasanur forest disease and tick-borne encephalitis viruses by the in silico approach. ( 29745301 )
2018
28
A new subtype of eastern tick-borne encephalitis virus discovered in Qinghai-Tibet Plateau, China. ( 29691370 )
2018
29
Virus RNA Load in Patients with Tick-Borne Encephalitis, Slovenia. ( 29912706 )
2018
30
A novel locus on mouse chromosome 7 that influences survival after infection with tick-borne encephalitis virus. ( 29976152 )
2018
31
Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection<i>In</i><i>Vitro</i>and in a Mouse Model. ( 29435494 )
2018
32
3'-O-Substituted 5-(perylen-3-ylethynyl)-2'-deoxyuridines as tick-borne encephalitis virus reproduction inhibitors. ( 29859999 )
2018
33
Brain perfusion alterations in tick-borne encephalitis-preliminary report. ( 29337197 )
2018
34
A matrix metalloproteinase 9 (MMP9) gene single nucleotide polymorphism is associated with predisposition to tick-borne encephalitis virus-induced severe central nervous system disease. ( 29496490 )
2018
35
A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016. ( 29667575 )
2018
36
Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10a8^years antibody persistence. ( 29397225 )
2018
37
Tick-borne encephalitis: A 43-year summary of epidemiological and clinical data from Latvia (1973 to 2016). ( 30422984 )
2018
38
Tick-borne encephalitis in Europe, 2012 to 2016. ( 30424829 )
2018
39
A Sensitive Nano Luciferase Immune Complex Assay System for Highly Sensitive and Specific Detection of Antibodies Against Tick-Borne Encephalitis Virus. ( 30431406 )
2018
40
Evaluation of NSE and S100B in patients with tick-borne encephalitis. ( 30468006 )
2018
41
Ticks and tick-borne encephalitis in Europe: Challenges for travel medicine. ( 30468875 )
2018
42
Perceptions of tick-borne encephalitis risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK. ( 30476160 )
2018
43
Comparison of Four Commercial IgG-Enzyme-Linked Immunosorbent Assays for the Detection of Tick-Borne Encephalitis Virus Antibodies. ( 30523740 )
2018
44
Epilepsia partialis continua following a Western variant tick-borne encephalitis. ( 30187304 )
2018
45
Ability of inactivated vaccines based on far-eastern tick-borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients. ( 30204244 )
2018
46
Case report: tick-borne encephalitis (TBE) in a Belgian traveller returning from Germany. ( 30204901 )
2018
47
Immunogenicity and Protective Activity of a Chimeric Protein Based on the Domain III of the Tick-Borne Encephalitis Virus E Protein and the OmpF Porin of Yersinia pseudotuberculosis Incorporated into the TI-Complex. ( 30274357 )
2018
48
Impact of pre-existing treatment with statins on the course and outcome of tick-borne encephalitis. ( 30286159 )
2018
49
Factors associated with severity of tick-borne encephalitis: A prospective observational study. ( 30296483 )
2018
50
Evaluation of antivirals against tick-borne encephalitis virus in organotypic brain slices of rat cerebellum. ( 30300398 )
2018

Variations for Tick-Borne Encephalitis

Expression for Tick-Borne Encephalitis

Search GEO for disease gene expression data for Tick-Borne Encephalitis.

Pathways for Tick-Borne Encephalitis

Pathways related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CCR5 CD209 CXCL10 GSN IFNL3 IL10
2
Show member pathways
12.99 CCR5 CXCL10 IFNL3 IL10 OAS1 OAS3
3 12.25 CXCL10 IL10 OAS1 TLR3
4
Show member pathways
12.24 CD209 CXCL10 OAS1 OAS3 TLR3
5 12.02 CXCL10 OAS1 OAS3
6 12 CCR5 GSN SCRIB
7
Show member pathways
11.95 CXCL10 CXCL11 IL10 OAS1 OAS3 TLR3
8 11.77 OAS1 OAS3 TLR3
9
Show member pathways
11.76 CCR5 CXCL10 CXCL11 GSN TLR3
10
Show member pathways
11.7 CCR5 CXCL10 CXCL11
11 11.35 CXCL10 CXCL11 IL10
12 11.13 CXCL10 OAS1
13 11.08 CXCL10 CXCL11
14 10.92 CXCL10 CXCL11 IL10
15
Show member pathways
10.86 IFNL3 OAS1
16 10.82 CCR5 CXCL10 IL10

GO Terms for Tick-Borne Encephalitis

Cellular components related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ALB CD209 CXCL10 CXCL11 GSN IFNL3
2 extracellular space GO:0005615 9.23 ALB CXCL10 CXCL11 GSN IFNL3 IL10

Biological processes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 CD209 OAS1 OAS3 TLR3
2 innate immune response GO:0045087 9.88 CD209 IFNL3 OAS1 OAS3 TLR3
3 regulation of signaling receptor activity GO:0010469 9.85 CXCL10 CXCL11 IFNL3 IL10
4 cytokine-mediated signaling pathway GO:0019221 9.81 CCR5 CXCL10 IFNL3 IL10
5 cell-cell signaling GO:0007267 9.77 CCR5 CXCL10 CXCL11
6 inflammatory response GO:0006954 9.77 CCR5 CXCL10 CXCL11 IL10 TLR3
7 chemotaxis GO:0006935 9.73 CCR5 CXCL10 CXCL11
8 cellular response to lipopolysaccharide GO:0071222 9.73 CCR5 CXCL10 CXCL11 IL10
9 chemokine-mediated signaling pathway GO:0070098 9.67 CCR5 CXCL10 CXCL11
10 defense response GO:0006952 9.62 CCR5 CXCL10 CXCL11 TLR3
11 negative regulation of mitotic cell cycle GO:0045930 9.58 IL10 SCRIB
12 negative regulation of viral genome replication GO:0045071 9.58 IFNL3 OAS1 OAS3
13 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.57 CXCL10 CXCL11
14 positive regulation of cAMP-mediated signaling GO:0043950 9.54 CXCL10 CXCL11
15 T cell chemotaxis GO:0010818 9.52 CXCL10 CXCL11
16 regulation of ribonuclease activity GO:0060700 9.46 OAS1 OAS3
17 response to virus GO:0009615 9.46 CXCL10 OAS1 OAS3 TLR3
18 leukocyte chemotaxis GO:0030595 9.43 CXCL10 CXCL11 IL10
19 immune response GO:0006955 9.43 CCR5 CXCL10 CXCL11 IL10 OAS1 OAS3
20 defense response to virus GO:0051607 9.02 CXCL10 IFNL3 OAS1 OAS3 TLR3

Molecular functions related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CXCL10 IFNL3 IL10
2 double-stranded RNA binding GO:0003725 9.33 OAS1 OAS3 TLR3
3 CXCR3 chemokine receptor binding GO:0048248 8.96 CXCL10 CXCL11
4 2'-5'-oligoadenylate synthetase activity GO:0001730 8.62 OAS1 OAS3
5 protein binding GO:0005515 10.06 ALB CCR5 CD209 CXCL10 CXCL11 GSN

Sources for Tick-Borne Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....